Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported a fourth-quarter loss of $1.43 per share on Monday, while revenue totaled ...
Stocktwits on MSN
DNTH stock soars after early 'go' decision for drug in autoimmune disorder program, boosting Wall Street optimism for potential launch
The “go” decision was reached early, ahead of the company’s second quarter expected timeline. ・The results from the interim analysis appear stronger than those reported by Sanofi's experimental drug ...
Shares of Dianthus Therapeutics rose after the company reached an early decision to move ahead with its phase 3 trial for Chronic Inflammatory Demyelinating Polyneuropathy, an autoimmune disorder. The ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...
An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...
DUBLIN--(BUSINESS WIRE)--The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. Chronic ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results